Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat ...Middle East

Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. The company has received the EOP2 meeting minutes, confirming the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat )

Also on site :

• Disneyland raises hopes for future Toy Story Midway Mania makeovers
• Thumbprint on cigarette carton leads to arrest in 1977 death of young woman
• PHOTO COLLECTION: Menendez Brothers